IRAK2 and COVID-19: Their downregulation in COVID‐19 patients induces production of IRAK1, IRAK2, and TRAF6 and potentially elicits transcriptomic alterations leading to hyperactivation of the immune system and hyperinflammation.15, 17, 43, 78